United Therapeutics Stock Price, News & Analysis (NASDAQ:UTHR)

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" UTHR shares.
View UTHR analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued 1 year price targets for United Therapeutics' stock. Their UTHR share price targets range from $230.00 to $314.00. On average, they anticipate the company's share price to reach $288.00 in the next year. This suggests a possible upside of 24.5% from the stock's current price.
View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts.

United Therapeutics' stock was trading at $278.09 at the beginning of the year. Since then, UTHR shares have decreased by 16.8% and is now trading at $231.32.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our UTHR earnings forecast.

United Therapeutics Co. (NASDAQ:UTHR) released its earnings results on Wednesday, November, 1st. The biotechnology company reported $5.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.28. The biotechnology company had revenue of $609.40 million for the quarter, compared to the consensus estimate of $585.82 million. United Therapeutics had a trailing twelve-month return on equity of 17.10% and a net margin of 40.82%. The company's revenue was up 18.1% compared to the same quarter last year. During the same period in the previous year, the company posted $4.91 earnings per share.

ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Subversive Mental Health ETF (SANE), Invesco Pharmaceuticals ETF (PJP), First Trust NYSE Arca Biotechnology Index Fund (FBT), Inspire Faithward Mid Cap Momentum ETF (GLRY), Formidable Fortress ETF (KONG), First Trust Health Care AlphaDEX Fund (FXH) and Alpha Intelligent - Large Cap Value ETF (AILV).

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

United Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (5.54%), Palo Alto Investors LP (1.23%), Bank of New York Mellon Corp (1.22%), AQR Capital Management LLC (1.01%), Fuller & Thaler Asset Management Inc. (0.92%) and Northern Trust Corp (0.83%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek.
View institutional ownership trends.

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.